Search

Displaying results 6561 - 6570 of 10000 in total
  1. Drug

    Benoxaprofen

    go.drugbank.com/drugs/DB04812
    ApprovedWithdrawn

    The holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.

  2. Drug

    Interferon Kappa

    go.drugbank.com/drugs/DB15749
    Experimental

    This gene encoding for this interferon is expressed in human epidermal keratinocytes. … interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in

  3. Drug

    Medetomidine

    go.drugbank.com/drugs/DB11428
    ExperimentalVet approved

    In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. … Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma.

  4. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].

  5. Drug

    Cefpirome

    go.drugbank.com/drugs/DB13682
    Approved

    Cefpirome is a β-lactam or cephalosporin.

  6. Drug

    Oxidronic acid

    go.drugbank.com/drugs/DB14159
    Approved

  7. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid.

  8. Drug

    Exametazime

    go.drugbank.com/drugs/DB11179
    Approved

    It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes.

  9. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.

    Synonyms: NBOH-2C-CN, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
  10. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose